CN104519891B - 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物 - Google Patents

用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物 Download PDF

Info

Publication number
CN104519891B
CN104519891B CN201380025599.8A CN201380025599A CN104519891B CN 104519891 B CN104519891 B CN 104519891B CN 201380025599 A CN201380025599 A CN 201380025599A CN 104519891 B CN104519891 B CN 104519891B
Authority
CN
China
Prior art keywords
cell
tbi
animal
cells
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380025599.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104519891A (zh
Inventor
C·V·博兰干
C·C·凯斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanbio Inc
University of South Florida St Petersburg
Original Assignee
Sanbio Inc
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanbio Inc, University of South Florida St Petersburg filed Critical Sanbio Inc
Priority to CN201910165600.6A priority Critical patent/CN109718250B/zh
Priority to CN202211044392.2A priority patent/CN115381855A/zh
Publication of CN104519891A publication Critical patent/CN104519891A/zh
Application granted granted Critical
Publication of CN104519891B publication Critical patent/CN104519891B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380025599.8A 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物 Active CN104519891B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910165600.6A CN109718250B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN202211044392.2A CN115381855A (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647893P 2012-05-16 2012-05-16
US61/647,893 2012-05-16
PCT/US2013/030895 WO2013172944A1 (en) 2012-05-16 2013-03-13 Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910165600.6A Division CN109718250B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN202211044392.2A Division CN115381855A (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Publications (2)

Publication Number Publication Date
CN104519891A CN104519891A (zh) 2015-04-15
CN104519891B true CN104519891B (zh) 2019-03-22

Family

ID=48040424

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380025599.8A Active CN104519891B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN201910165600.6A Active CN109718250B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN202211044392.2A Pending CN115381855A (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910165600.6A Active CN109718250B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN202211044392.2A Pending CN115381855A (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Country Status (7)

Country Link
US (4) US9828593B2 (https=)
EP (1) EP2849766B1 (https=)
JP (6) JP6134783B2 (https=)
CN (3) CN104519891B (https=)
AU (2) AU2013263417B2 (https=)
CA (1) CA2872188C (https=)
WO (1) WO2013172944A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104519891B (zh) 2012-05-16 2019-03-22 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
WO2014058464A1 (en) 2012-10-09 2014-04-17 Sanbio, Inc. Methods and compositions for treatment of retinal degeneration
WO2015120388A1 (en) * 2014-02-10 2015-08-13 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
HK1247080A1 (zh) 2015-04-01 2018-09-21 桑比欧公司 用於刺激细胞增殖和提供fgf2同种型的生物活性混合物的方法和组合物
KR101986366B1 (ko) * 2016-02-26 2019-06-07 주식회사 이노퓨틱스 Ｎｕｒｒ１과 Ｆｏｘａ２의 교질세포 기능 조절에 의한 염증성 신경질환 치료
EP3423070B1 (en) * 2016-03-03 2022-05-04 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
WO2018125829A1 (en) * 2016-12-28 2018-07-05 Sanbio, Inc. Cell delivery system and methods of operation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101008033A (zh) * 2006-01-27 2007-08-01 陈云 功能性中枢神经损伤诊断检测用基因芯片及其制造方法
CN100497621C (zh) * 2002-02-06 2009-06-10 桑比欧公司 通过导入notch基因将骨髓基质细胞诱导分化为神经细胞或骨骼肌细胞的方法
CN101801396A (zh) * 2007-08-15 2010-08-11 桑比欧公司 治疗神经变性的方法和组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
JP3886346B2 (ja) 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
US20050032827A1 (en) 2003-06-12 2005-02-10 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
EP1737950B9 (en) 2004-04-12 2012-04-18 Sanbio, Inc. Cells exhibiting neuronal progenitor cell characteristics
PT1855700E (pt) * 2005-03-07 2013-12-10 Sanbio Inc Utilização de materiais para tratamento de lesões do sistema nervoso central
WO2008102460A1 (en) 2007-02-23 2008-08-28 Sanbio Inc. Transplantation of bone marrow stromal cell-induced neural stem cells for promoting fuctional recovery after spinal cord injury
EP2215216B1 (en) 2007-12-03 2018-05-30 SanBio, Inc. Extracellular matrix from pluripotent cells
PT2222839E (pt) 2007-12-03 2015-11-30 Sanbio Inc Métodos e composições para modular a diferenciação de células pluripotentes
ES2594229T3 (es) 2008-04-30 2016-12-16 Sanbio, Inc. Células de regeneración nerviosa con alteraciones en la metilación del ADN
EP2694080B1 (en) 2011-04-06 2018-03-14 SanBio, Inc. Methods and compositions for modulating peripheral immune function
US20120263681A1 (en) 2011-04-12 2012-10-18 Fujifilm Corporation Composition comprising cell and biocompatible polymer
JP6306506B2 (ja) 2011-08-19 2018-04-04 サンバイオ，インコーポレイティド 神経原生及びグリア原生因子及びそれらについてのアッセイ
CN112386681A (zh) 2012-01-27 2021-02-23 桑比欧公司 用于调节血管生成和血管发生的方法和组合物
CN104519891B (zh) 2012-05-16 2019-03-22 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100497621C (zh) * 2002-02-06 2009-06-10 桑比欧公司 通过导入notch基因将骨髓基质细胞诱导分化为神经细胞或骨骼肌细胞的方法
CN101008033A (zh) * 2006-01-27 2007-08-01 陈云 功能性中枢神经损伤诊断检测用基因芯片及其制造方法
CN101801396A (zh) * 2007-08-15 2010-08-11 桑比欧公司 治疗神经变性的方法和组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mo A Dao1 et al.."Comparing the immunosuppressive potency of naïve marrow stromal cells and Notch-transfected marrow stromal cells".《Journal of Neuroinflammation》.2011,第1-14页。. *

Also Published As

Publication number Publication date
JP2025098021A (ja) 2025-07-01
EP2849766B1 (en) 2019-03-06
US20190185839A1 (en) 2019-06-20
US20140186316A1 (en) 2014-07-03
EP2849766A1 (en) 2015-03-25
JP2018111733A (ja) 2018-07-19
US20200354709A1 (en) 2020-11-12
US20150197741A1 (en) 2015-07-16
JP2023099213A (ja) 2023-07-11
AU2016204910A1 (en) 2016-08-04
AU2016204910B2 (en) 2017-07-20
US9828593B2 (en) 2017-11-28
CN104519891A (zh) 2015-04-15
CA2872188C (en) 2018-08-14
HK1206631A1 (en) 2016-01-15
CN109718250B (zh) 2022-08-30
CA2872188A1 (en) 2013-11-21
WO2013172944A1 (en) 2013-11-21
JP2016220694A (ja) 2016-12-28
JP2021098738A (ja) 2021-07-01
JP2015517520A (ja) 2015-06-22
JP6134783B2 (ja) 2017-05-24
AU2013263417A1 (en) 2014-11-20
CN109718250A (zh) 2019-05-07
CN115381855A (zh) 2022-11-25
AU2013263417B2 (en) 2016-05-26
US10626389B2 (en) 2020-04-21

Similar Documents

Publication Publication Date Title
CN104519891B (zh) 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN101748096B (zh) 亚全能干细胞、其制备方法及其用途
Kerkis et al. Neural and mesenchymal stem cells in animal models of Huntington’s disease: past experiences and future challenges
US20060247195A1 (en) Method of altering cell properties by administering rna
CN112891374B (zh) 治疗中风的影响的方法
Trueman et al. Repair of the CNS using endogenous and transplanted neural stem cells
JP2018511599A (ja) 細胞増殖の刺激のための方法及び組成物、ならびにｆｇｆ２アイソフォームの生物学的に活性な混合物の提供
KR20090055691A (ko) 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물
Dori et al. Seven days post-injury fate and effects of genetically labelled adipose-derived mesenchymal cells on a rat traumatic brain injury experimental model
WO2024160181A1 (zh) 外泌体、其制备方法、其用途以及医药组合物
Luo et al. Biological behavioral alterations of the post-neural differentiated dental pulp stem cells through an in situ microenvironment
HK40077940A (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK40007760A (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK40007760B (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK1206631B (en) Cells for use in the treatment of brain injury
ES2347121B1 (es) Celulas madre multipotenciales obtenidas del timo de un adulto.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant